Account

Search results for: orphan drugs

Health Technology Assessment: HTACG provide update...

We discuss the updates on EU HTA from the June meeting of the Member State Coordination Group on Hea...

Read more
Navigating the new EU HTA regulation: organisation...

Our latest article summarises the key changes to be aware of for the upcoming EU HTA, as well as imp...

Read more
How will recent safety signals impact patient acce...

Safety signals have sparked vital discussions on patient access to ATMPs, marking a pivotal moment i...

Read more
AML treatment Tibsovo earns key rating in Germany

Tibsovo (ivosidenib) has been granted a major additional benefit rating for its use as a first-line ...

Read more
NICE’s Proportionate Approach to Technology ...

Webinar: Our experts discuss NICE's proportionate approach to technology appraisals and the implicat...

Read more
EU HTA and what it means for manufacturers

Oncology products, advanced therapy medicinal products (ATMPs) and medical devices are entering the ...

Read more
What are Joint Scientific Consultations and why th...

We explore joint scientific consultations; what they mean and why they are important to manufacturer...

Read more
What is the joint clinical assessment and what doe...

We explore what the joint clinical assessment (JCA) is, its process and what future developments may...

Read more
PMA Insights: Week 11

We summarise key pharmaceutical, pricing and market access insights that are worth reading about thi...

Read more
The Financial Stabilisation Act is unlikely to off...

DAK-Gesundheit claim that cost saving measures imposed by the GVK Financial Stabilisation Act are un...

Read more
Older
Newer

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.

Talk to an expert

Remap Consulting have significant experience working with pharmaceutical and biotech companies in helping them navigate global market access.​

Get in touch